Some Eph receptors, especially EphA2 is often overexpressed and functionally altered in many cancers including breast (26), ovarian (27), and endometrial (28, 29) carcinomas, which correlated with, e.g., increased invasiveness, increased metastatic potential, prominent vascularization, and consequently with poor patient outcome. Here, EPHA2 is linked to carcinoma.